https://stockhub.co/index.php?action=history&feed=atom&title=TaiMed_Biologics_Inc. 2026-04-03T20:36:31Z Revision history for this page on the wiki MediaWiki 1.43.5 https://stockhub.co/index.php?title=TaiMed_Biologics_Inc.&diff=95976&oldid=prev 2022-09-26T07:07:00Z

<p>Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; == TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; T...&quot;</p> <p><b>New page</b></p><div>== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==<br /> <br /> TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.<br /> <br /> == References and notes == <br /> [[Category:Thesis]]<br /> __INDEX__</div>

95.149.241.133